Valuation: Vectus Biosystems Limited

Market Cap 7.69M 5.33M 4.66M 4.28M 3.99M 7.57M 508M 51.42M 19.99M 250M 20.01M 19.58M 860M P/E 2024
-1.75x
P/E 2025 -1.2x
Enterprise Value 7.64M 5.3M 4.63M 4.25M 3.97M 7.52M 504M 51.08M 19.86M 248M 19.88M 19.45M 854M EV / Sales 2024
2.91x
EV / Sales 2025 4.35x
Free-Float
56.44%
Yield 2024 *
-
Yield 2025 -
1 day-11.54%
1 week-8.00%
Current month-8.00%
3 months-23.33%
6 months-30.30%
Current year-36.11%
1 week 0.12
Extreme 0.115
0.14
1 month 0.1
Extreme 0.1
0.18
Current year 0.09
Extreme 0.09
0.18
1 year 0.04
Extreme 0.037
0.46
3 years 0.04
Extreme 0.037
0.5
5 years 0.04
Extreme 0.037
2.2
10 years 0.04
Extreme 0.037
2.2
Manager TitleAgeSince
Chief Executive Officer - 2026-05-06
Corporate Secretary - 2015-07-08
Director TitleAgeSince
Director/Board Member - 2005-12-11
Chairman - 2018-08-30
Director/Board Member - 2024-12-19
Change 5-day change 1-year change 3-year change Capi.($)
-11.54%-8.00%+202.63%-73.86% 4.9M
+1.70%+7.41%+2.50%+8.22% 49.92B
+0.92%+3.93%+399.71%+605.33% 40.23B
+1.89%+8.32%+26.06%-6.35% 34.55B
+2.38%+6.35%+21.25%+64.58% 33.09B
+3.96%+10.67%+8.30%+40.44% 27.51B
+2.51%+5.27% - - 17.05B
+2.58%+5.79%+73.44%+133.27% 15.92B
+0.32%+0.58%+14.00%+19.59% 13.86B
+3.30%+0.76%+90.23%+99.12% 13.52B
Average +0.80%+4.44%+93.12%+98.93% 24.57B
Weighted average by Cap. +2.07%+6.53%+90.20%+137.90%

Financials

2024 2025
Net sales 1.14M 790K 690K 634K 591K 1.12M 75.19M 7.62M 2.96M 36.96M 2.96M 2.9M 127M 478K 332K 290K 266K 248K 471K 31.58M 3.2M 1.24M 15.52M 1.24M 1.22M 53.49M
Net income -2.34M -1.62M -1.42M -1.3M -1.21M -2.3M -154M -15.64M -6.08M -75.89M -6.09M -5.96M -262M -1.78M -1.23M -1.08M -990K -923K -1.75M -117M -11.89M -4.62M -57.69M -4.63M -4.53M -199M
Net Debt -780K -541K -473K -435K -405K -768K -51.51M -5.22M -2.03M -25.32M -2.03M -1.99M -87.25M -50.99K -35.36K -30.91K -28.41K -26.48K -50.23K -3.37M -341K -133K -1.66M -133K -130K -5.7M
Logo Vectus Biosystems Limited
Vectus Biosystems Limited is an Australia-based drug discovery and development company. The Company focuses on medical research and development. It is engaged in developing a treatment for fibrosis and high blood pressure, which includes the treatment for diseases in the fibrotic market, namely heart, kidney, and liver diseases. Its compound, VB0004, focuses on treating the hardening of functional tissue and high blood pressure. It also focuses on developing candidates for the treatment of fibrotic liver diseases, including non-alcoholic steatohepatitis (NASH) as well as pulmonary fibrotic diseases. The Company has also developed technology focused at improving the speed and accuracy of measuring the amount of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) in samples tested in laboratories. Accugen is a platform, developed by its wholly owned subsidiary, Accugen Pty Limited, comprising of reagents, and software that quantitate polymerase chain reaction (qPCR) reactions.
Employees
-
Date Price Change Volume
26-07-03 A$0.1150 -11.54% 30,000
26-07-02 A$0.1300 +4.00% 86,727
26-06-29 A$0.1250 0.00% 7,635
26-06-26 A$0.1250 0.00% 368,860